<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <p class="gem-c-title__context">
      Guidance
    </p>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    How Marketing Authorisation Applications referred under Article 29 will be handled after Brexit
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">How the MHRA will assess Marketing Authorisation Applications (MAA) for medicines referred under Article 29 if there's a no-deal Brexit.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 18 March 2019
    <br></br>Last updated 10 October 2019
      — <a href="#history" class="app-c-published-dates__history-link govuk-link">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>




<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body">
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<div class="call-to-action">
<h2 id="stay-up-to-date">Stay up to date</h2>

<p>Get ready for Brexit on 31 October 2019. This page tells you how to prepare for Brexit. It will be updated if anything changes, including if a deal is agreed.</p>

<p><a href="https://www.gov.uk/email-signup/?topic=/government/brexit">Sign up to email alerts</a> to get the latest information.</p>
</div>

<p>Article 29 referrals are triggered when a consensus cannot be reached between Member States on the outcome for a Marketing Authorisation Application (<abbr title="Marketing Authorisation Application">MAA</abbr>) which has been evaluated in a mutual-recognition procedure (<abbr title="mutual-recognition procedure">MRP</abbr>) or decentralised procedure (<abbr title="Decentralised procedure">DCP</abbr>), on the grounds of a potential serious risk(s) to public health (<abbr title="potential serious risk(s) to public health">PSRPH</abbr>).</p>

<h2 id="how-we-will-treat-maas-at-different-stages-of-the-process-on-exit-day">How we will treat MAAs at different stages of the process on exit day</h2>

<p>For MAAs that have been referred under Article 29, where either a positive or negative opinion has been taken at the Coordination Group for Mutual Recognition and Decentralised Procedures - Human (<abbr title="Coordination Group for Mutual Recognition and Decentralised Procedures - Human">CMDh</abbr>) or the Committee for Medicinal Products for Human Use (<abbr title="Committee for Medicinal Products for Human Use">CHMP</abbr>) but no decision issued by the time the UK leaves the <abbr title="European Union">EU</abbr>, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will either grant or refuse the application with regard to the relevant committee decision.</p>

<p>For all pending MAAs submitted in the UK, either as Reference Member State (<abbr title="Reference Member State">RMS</abbr>) or Concerned Member State (<abbr title="Concerned Member State">CMS</abbr>), that have been referred under Article 29 before the UK leaves the <abbr title="European Union">EU</abbr> but no opinion has been reached by <abbr title="Coordination Group for Mutual Recognition and Decentralised Procedures - Human">CMDh</abbr> or <abbr title="Committee for Medicinal Products for Human Use">CHMP</abbr>, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will complete the assessment as a national procedure.</p>

<p>The <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment will take into account the existing <abbr title="Reference Member State">RMS</abbr> and <abbr title="Concerned Member State">CMS</abbr> assessments with particular focus on the identified <abbr title="potential serious risk(s) to public health">PSRPH</abbr>. If the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> are minded to refuse an application based on a <abbr title="potential serious risk(s) to public health">PSRPH</abbr>, consultation with the Commission on Human Medicines (<abbr title="Commission on Human Medicines">CHM</abbr>) and other relevant expert advisory committees will take place.</p>

<p>On completion of the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> assessment, and consultation with expert advisory committees as required, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will issue its decision on approval or refusal of the Marketing Authorisation.</p>

<p>For applications where the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> had a positive opinion at Day 210 of a <abbr title="Decentralised procedure">DCP</abbr> or Day 90 of an <abbr title="mutual-recognition procedure">MRP</abbr>, and considered that the risk/benefit of the product is positive in the subsequent referral procedure, a Marketing Authorisation will be granted following receipt of UK product information.</p>

<p>No additional or different fee will be charged for applications that are completed as a national procedure having previously been referred under Article 29. If a Marketing Authorisation applicant does not wish the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> to continue with the <abbr title="Decentralised procedure / mutual-recognition procedure">DCP/MRP</abbr> as a national application, the applicant should submit a withdrawal letter to the UK.</p>

<p>This guidance will apply from exit day in line with the <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made">Human Medicines Regulations (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates app-c-published-dates--history" id="history" data-module="toggle" lang="en">
    Published 18 March 2019
    <br></br>Last updated 10 October 2019
      <a href="#full-history" class="app-c-published-dates__toggle govuk-link" data-controls="full-history" data-expanded="false" data-toggled-text="- hide all updates">+ show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden" id="full-history">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-10-10T12:53:01.000+01:00">10 October 2019</time>
              Updated page title and summary to clarify this is about Marketing Authorisation Applications for medicines referred under Article 29. The rest of the page has not changed.
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-10-09T12:31:37.000+01:00">9 October 2019</time>
              Change of text within Stay up to date box.
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-03-18T13:55:00.000+00:00">18 March 2019</time>
              First published.
            </li>
        </ol>
      </div>
</div>

      </div>

  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">

    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-a98b5e93" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-related_items-a98b5e93" data-module="gem-toggle">


  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.1 Related content" data-track-label="/find-eu-exit-guidance-business" data-track-options="{"dimension28":"1","dimension29":"Find Brexit guidance for your business"}" href="/find-eu-exit-guidance-business">Find Brexit guidance for your business</a></li>

  </ul>
</nav>



      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-a98b5e93" data-module="gem-toggle">

    <h3 id="related-nav-collections-a98b5e93" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="2.1 Collection" data-track-label="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario" data-track-options="{"dimension28":"1","dimension29":"MHRA guidance and publications about a possible no-deal Brexit"}" href="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario">MHRA guidance and publications about a possible no-deal Brexit</a></li>

  </ul>
</nav>

  </div>


</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-87330bdb" data-module="gem-toggle">

    <h2 id="related-nav-topics-87330bdb" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"1","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>